Roche Reassesses Esbriet's Future Amidst Generic Drug Competition

Esbriet, an oral anti-fibrotic medicine, represents a significant advancement in treating idiopathic pulmonary fibrosis, a condition that scars the lungs and relentlessly impairs breathing. Approved in approximately 40 countries, Esbriet's efficacy in slowing disease progression made it a cornerstone in managing this incurable disease.